‎Avalon’s Generic Mounjaro Is Not Yet Saudi-Made

Mounjaro, Eli Lilly’s tirzepatide-based drug.

Avalon Pharma has actually put a great deal on its licence to offer a generic variation of tirzepatide, the drug Eli Lilly markets as Mounjaro and Zepbound.

It has not put a date on it. The information indicate a long haul, and a longer one for tirzepatide made in Saudi Arabia.

The licence, concurred with India’s OneSource Specialty Pharma, is anticipated to create cumulative income of a minimum of SAR800 million in the very first 5 years after launch, throughout Saudi Arabia and other markets in the Middle East and North Africa.

Spread equally, that is SAR160 million a year, about 35% of Avalon’s 2025 earnings of SAR460.5 million. That is an illustration of scale, not a projection. The statement does not state just how much would originate from Saudi Arabia.

The arrangement sets a condition instead of a date. Each market can introduce just after the pertinent patents end, both there and in the nation of manufacture.

Absolutely nothing Avalon has actually stated because fills that space. Its third-quarter outcomes cover the duration to 30 September, before the offer was signed.

In remarks to Argaam on 4 November, Avalon associated its outlook to private-sector sales, exports, federal government tenders and brand-new production capability. The licence was not amongst them, and no schedule was provided for it.

The patent calendar for that reason matters. The Geneva-based Medicines Patent Pool anticipates the primary tirzepatide patent to end in 2036 in the low- and middle-income nations where it has actually been approved, and Lilly’s later patents on the injection’s dish in 2039. Neither date has actually been validated for Saudi Arabia.

Eli Lilly’s later patents on the injection’s dish have actually been submitted and approved commonly in the very same nations and are anticipated to end in 2039. These figures do not cover Saudi Arabia, a high-income nation, where the patent position still requires validating.

Where the drug is made matters as much as who offers it, and the statement does not state where that will be.

If it is made in India, where a dish patent was approved in March 2025, Indian patents might set the schedule, and sales may not start till after 2036 unless OneSource’s variation prevents the dish patents.

Avalon will hold the marketing authorisation for a multi-dose pen in 6 strengths, from 2.5 mg to 15mg, and can ask OneSource to move the production innovation.

It can do so just after business launch, nevertheless, and the statement sets no dedication or schedule.

A transfer for that reason can not be utilized to move production somewhere else and release earlier. Where it is made need not slow approval: Saudi Arabia’s drug regulator fast-tracks the very first generic variation of a medication, anywhere it is produced.

Avalon does not yet make injectable medications. Its plants produce tablets, pills, liquids, creams and other topical items.

Injections will feature Avalon 4, a brand-new plant for cancer, injectable and eye medications due for conclusion at the end of 2027, long before any tirzepatide launch. The plant itself is for that reason not likely to be the restraint.

The open concern is what a transfer would cover: filling and putting together the pens in Saudi Arabia, or making tirzepatide itself, the more intricate action. The distinction matters: the regulator’s localisation path uses just if every phase of production happens in the Kingdom.

The Saudi Food and Drug Authority’s brand-new assistance, released on 14 October 2026 and working on 1 January 2027, accepts partial regional production just for biological items.

Tirzepatide is managed as a standard drug, so filling pens alone would not certify.

Individually, items under the authority’s Pharmaceutical Industry Transfer and Localization Initiative should satisfy extra local-manufacturing conditions. A minimum of in the beginning, the offer protects the right to offer tirzepatide, not to make it in Saudi Arabia.

Beyond the Kingdom, the licence would extend a local service that is still little. Exports comprised 13% of Avalon’s 2025 profits, with current development led by the UAE, Iraq, Kuwait and Oman.

Markets require not open at the very same time, and the statement does not state whether the five-year earnings window, or the ten-year agreement term, begins with the very first launch anywhere or individually in each nation. That matters if markets open years apart.

Egypt’s path is currently taken

Egypt uses no apparent faster way. Avalon is constructing a company there through agreement production and circulation arrangements, with profits targeted from 2027, however has actually not stated that tirzepatide becomes part of that strategy.

The statement does not call the marketplaces the licence covers, so it is unclear that Egypt is among them. Even if it is, the right to take control of production uses just after launch. Lilly is likewise currently developed there.

Its regional partner, EVA Pharma, holds the marketing authorisation for Mounjaro, made the initial item readily available previously in 2025 and introduced the KwikPen in July that year.

By the time the licence pays, it might likewise weigh less in Avalon’s outcomes than today’s figures recommend: third-quarter earnings increased 15.2% to SAR124.4 million. On what Avalon has actually divulged, Saudi worth has no start date. It should wait on patents to end in Saudi Arabia and in the nation where the drug is made, and worth made in the Kingdom would come later on still.

Avalon can look for to take control of making just after launch. Even then, the item would count as in your area made just if every production action relocated to the Kingdom, consisting of making the active component. Up until a launch date appears, the licence is finest valued as an alternative on Avalon’s future instead of a line in income projections.

4 advancements will reveal whether that judgement holds. The very first is whether Avalon states when the five-year earnings duration starts: with the very first launch anywhere, or individually in each nation.

The 2nd is verification, from the Saudi patent signs up, of when Lilly’s patents end in the Kingdom.

The 3rd is an application by Avalon to the Saudi Food and Drug Authority. The guidelines enable one as much as 2 years before the patent ends, so a filing would indicate that launch is close.

The last comes just after launch: whether Avalon asks to take control of production, and whether it would make the drug itself or just fill and put together the pens.

Editorial Note

We release without bylines. Our research study is produced jointly– experts, editors and information experts dealing with the exact same concerns– and the findings show the judgement of the group instead of any person.

This is a purposeful option. It keeps the argument, instead of its author, as the important things a reader weighs.

Every figure here was calculated by Argaam experts from the sources pointed out, and is reproducible from them. The analysis and conclusions are the group’s own. Charts were rendered with AI help. Method and workbook offered to customers; concerns to [email protected].